GlobeNewswire by notified

Aspo's financial targets and dividend policy updated, and profitability metric of the guidance changed


Aspo Plc
Stock Exchange Release
Other information disclosed according to the rules of the Exchange
May 14, 2024, at 8:05 a.m.

Aspo's financial targets and dividend policy updated, and profitability metric of the guidance changed

Aspo holds a Capital Markets Day today, May 14, 2024, starting at 9.30 a.m. [(EEST)] in Helsinki. Aspo Group’s new portfolio vision, disclosed earlier today, along with the adjusted long-term financial targets, ESG commitment, business strategies, dividend policy as well as current state of Aspo's business operations and prospects will be presented at the event.

Revised financial targets

Aspo’s long-term financial targets remain fundamentally unchanged, but they have been slightly adjusted to consider the compounder strategy and management of growth financing. Key changes include change from operating profit (EBIT) to operating profit excluding amortization of intangible assets (EBITA) to mitigate the impact of amortization in M&A transactions, which will gradually build-up due to the compounder strategy, as well as replacing the gearing target with a target for Net debt / comparable EBITDA of below 3.0, to manage the growth financing in relation to development of financial performance.

Aspo’s adjusted long-term financial targets are:

  • EBITA of 8% (New: operating profit excluding amortization of intangible assets (EBITA), previously operating profit (EBIT))
    • Telko 8%
    • Leipurin 5%
    • ESL 14%
  • Net sales growth 5–10% per year (New: defined as the minimum annual growth level to be achieved)
  • Return on equity over 20%
  • New: Net debt / comparable EBITDA below 3.0 (previously: Gearing less than 130%)

Updated dividend policy

To support the growth strategy execution, Aspo’s dividend policy has been updated to reflect company strategy and growth ambition, the ongoing transition and specific business characteristics. Aspo's revised dividend policy:

  • Aspo’s dividend growth is based on positive profitability development with the aim to pay-out annually up to 50% of net profit as dividend. The goal is to gradually increase the amount of dividends, while considering financing needs of growth initiatives with strategic priority.

Profitability metric of the guidance changed from EBIT to EBITA, assumptions behind the guidance for year 2024 remain unchanged

Assumptions behind the guidance for year 2024 remain unchanged. The guidance for year 2024 has been changed to the new profitability metric operating profit excluding amortization of intangible assets (EBITA) (previously operating profit (EBIT)). New guidance for 2024 is:

Aspo Group’s comparable EBITA is expected to exceed EUR 32 million in 2024 (2023: EUR 27.9 million)

For reference, Aspo Group’s previous guidance for 2024 with the old profitability metric operating profit was:
Aspo Group’s comparable operating profit is expected to exceed EUR 30 million in 2024 (2023: EUR 26.5 million). 

Capital Markets Day webcast and presentation materials

The webcast can be followed live on Aspo's website ( from 9.30 a.m. today. Webcast recording and presentation materials (in English) will be available on the website after the event.

"We are delighted to continue to execute clear and successful business strategies for all three segments. ESL Shipping is focused on sustainability-driven growth, combined with commercial and operational excellence. Telko’s strategy is focused on organic growth supported by M&A and scalability. Leipurin continues its path to full profit potential through prioritised growth initiatives and development of commercial, supply chain and sourcing capabilities. We are also keen for sustainability to continue to shape our business strategies. Aspo Group’s ambition is that Aspo and its businesses will commit to Science Based Targets by the end of 2024. Each of Aspo's businesses aim to be a sustainability forerunner in its industry", says Rolf Jansson, CEO of Aspo Group.

Rolf Jansson

Further information:
Rolf Jansson, CEO, tel. +358 400 600 264,
Erkka Repo, CFO, tel. +358 405 827 971,


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued


Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye